GLYC - グリコ・ミメティックス (GlycoMimetics Inc.) グリコ・ミメティックス



symbol GLYC
会社名 GlycoMimetics Inc (グリコ・ミメティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 GlycoMimetics Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate GMI-1070 (Rivipansel) for the treatment of vaso-occlusive crisis (VOC) a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271 a specific E-selectin inhibitor to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate GMI-1359 that targets both E-selectin and a chemokine receptor CXCR4. The Company is also advancing other preclinical-stage programs which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.   グリコ・ミメティックスは希少薬の発見と開発を行う米国のバイオ医薬品会社。鎌状赤血球病患者の血管閉鎖性発作の治療薬GMI-1070、急性骨髄性白血病と血液凝固障害の治療薬GMI-1271の治験を行う。また、緑膿菌毒性因子をタ―ゲットにした治療薬の開発を行う。   GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has an ongoing Phase 1b clinical trial evaluating GMI-1359, a combined CXCR4 and E-selectin antagonist, also a wholly-owned drug candidate. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.
本社所在地 9708 Medical Center Drive Rockville MD 20850 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-243-1201
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear 2014年
EBITDA EBITDA(百万ドル) -41.46510
終値(lastsale) 13.62
時価総額(marketcap) 586439976.54
時価総額 時価総額(百万ドル) 609.26030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 379.82560
当期純利益 当期純利益(百万ドル) -39.99956
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 GlycoMimetics Inc revenues was not reported. Net loss increased 42% to $22.8M. Higher net loss reflects researcg and development expense balanc increase of 59% to $17.5M (expense) General_Administrative Expe increase of 26% to $4.3M (expense) Stock-based Compensation in R&D increase of 36% to $853K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.59.



   GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare Conference. Ms. Kings presentation will take place from 2:30 to 2:55 p.m. on June 3, 2021.
   GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study  2021/05/26 13:22:39 Seeking Alpha
   Glycomimetics Inc (GLYC) falls 0.78% for May 19  2021/05/19 22:00:19 Equities
Glycomimetics Inc (NASDAQ: GLYC) shares fell -0.78% to end trading Wednesday at $2.53 per share - a net change of $-0.02. Shares traded between $2.77 and $2.47 throughout the day. 2867458 shares of Glycomimetics Inc exchanged hands. Visit Glycomimetics Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Glycomimetics Inc and to follow the companys latest updates, you can visit the companys profile page here: Glycomimetics Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.
   GlycoMimetics A Buy On Potential 2022 AML Data  2021/05/19 13:06:41 Seeking Alpha
   GlycoMimetics, Inc. (NASDAQ:GLYC): Heres Whats Really Going On  2021/05/17 13:00:00 Stocks Register
The trading price of GlycoMimetics, Inc. (NASDAQ:GLYC) closed lower on Friday, May 14, closing at $2.52, -4.37% lower than its previous close. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Traders who pay close attention to intraday price movement should know that it fluctuated between $2.3400 GlycoMimetics, Inc. (NASDAQ:GLYC): Heres Whats Really Going On Read More »
   GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study  2021/05/26 13:22:39 Seeking Alpha
   Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML  2021/03/04 13:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China. “Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that A
   GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020  2021/03/02 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million. “During 2020, we remained on track to complete enrollment of our uproleselan pivotal trial in the second half of 2021. Uproleselan continues to have strong support from c
   GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences  2021/02/26 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investors tab. Details are as follows: Cowen 41st Annual Health Care Conference March 1 – March 4, 2021 Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in
   GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2  2021/02/23 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all c
   GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer  2021/02/23 14:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our ma

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 グリコ・ミメティックス GLYC GlycoMimetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)